[1] van Bokhoven H. Genetic and epigenetic networks in intellectual disabilities[J]. Annu Rev Genet, 2011, 45: 81-104. [2] Gregor A, Oti M, Kouwenhoven EN, et al. De novo mutations in the genome organizer CTCF cause intellectual disability[J]. Am J Hum Genet, 2013, 93: 124-131. [3] 陈兰,赫纹,刘玲. 1例新生儿常染色体显性智力障碍21型病例报告[J]. 中国当代儿科杂志,2021,23:306-309. [4] Kim S, Yu NK, Kaang BK. CTCF as a multifunctional protein in genome regulation and gene expression[J]. Exp Mol Med, 2015, 47: e166. doi: 10.1038/emm.2015.33 [5] Ohlsson R, Lobanenkov V, Klenova E. Does CTCF mediate between nuclear organization and gene expres-sion?[J]. Bioessays, 2010, 32: 37-50. [6] Ren G, Jin W, Cui K, et al. CTCF-mediated enhancer-promoter interaction is a critical regulator of cell-to-cell variation of gene expression[J]. Mol Cell, 2017, 67: 1049-1058. [7] Zuin J, Dixon JR, van der Reijden MI, et al. Cohesin and CTCF differentially affect chromatin architecture and gene expression in human cells[J]. Proc Natl Acad Sci USA, 2014, 111: 996-1001. [8] Bastaki F, Nair P, Mohamed M, et al. Identification of a novel CTCF mutation responsible for syndromic intellec-tual disability-a case report[J]. BMC Med Genet, 2017, 18: 68. doi: 10.1186/s12881-017-0429-0. [9] Chen F, Yuan H, Wu W, et al. Three additional de novo CTCF mutations in Chinese patients help to define an emerging neurodevelopmental disorder[J]. Am J Med Genet C Semin Med Genet, 2019, 181: 218-225. [10] Hori I, Kawamura R, Nakabayashi K, et al. CTCF deletion syndrome: clinical features and epigenetic delineation[J]. J Med Genet, 2017, 54: 836-842. [11] Konrad EDH, Nardini N, Caliebe A, et al. CTCF variants in 39 individuals with a variable neurodevelopmental disorder broaden the mutational and clinical spectrum[J]. Genet Med, 2019, 21: 2723-2733. |